Jeff co-leads the Digital Health and Health IT Practice at Health Advances. His 15-year career in healthcare spans digital health and therapeutics, medtech, biopharma, and healthcare services. He holds extensive expertise related to commercialization, global market access, product development, and evidence generation.

Prior to joining Health Advances, Jeff held executive roles in market access, trade, and commercial functions at Akili Interactive, an industry leading digital therapeutics company. During his time at Akil Interactive, Jeff focused on payer strategy, reimbursement, pricing, strategic partnerships, evidence generation, distribution, launch planning and execution.

In addition to his work at Akili, he has served as a Digital Therapeutics task group co-lead for the National Council of Prescription Drug Programs and a Scientific Leadership Board Member for the Digital Medicine Society.

Prior to his time at Akili Interactive, Jeff served as Senior Director for the Medicines Company in their Value Development department. He supported commercialization and global launch of novel drug device combo and the development of additional perioperative and cardiovascular products. Prior to The Medicines Company, Jeff served as a consultant for GfK working in global market access and commercialization. His work spanned numerous therapeutic areas across drug, devices, and diagnostics.

Jeff holds a Master of Science in Physical Therapy and an MBA with a specialization in Health Sector Management from Boston University.

Mitali is a medical device and pharmaceutical executive with over 25 years of diverse experience spanning injectables, implantables, infusion and injection drug delivery devices. She has a successful track record of developing, industrializing and commercializing medical devices and combination products. Mitali is currently the VP and Global Head of the Medical Device Development unit at Sanofi. Prior to that she worked at companies such as Becton Dickinson, where she and her team were instrumental in developing and launching the first terminally sterilized prefilled syringe used for maintaining patency of VADs; as well as at Bristol Myers Squibb, where she established BMS’ device strategy, process, governance, quality system, and team structure to operationalize that strategy, leading to the launch of BMS’ first drug-device combination product. Mitali is a Biomedical Engineer by academic training, is six sigma green belt certified, and has several issued patents.

Irene Barquero is a seasoned leader in the medical industry with over 20 years of experience driving operational excellence and innovation. As Senior Director of Operations at Hologic in Marlborough, Massachusetts, she oversees strategic initiatives that enhance manufacturing efficiency and cost enhancements in the medical technology sector.

Throughout her tenure at Hologic, Irene has played a pivotal role in managing New Product Introduction, Process Engineering, and Manufacturing Engineering across the company’s Costa Rica and Marlborough sites. Her expertise in scaling operations and optimizing manufacturing processes has contributed to the successful launch of numerous groundbreaking medical devices.

Originally from Costa Rica, Irene and her family migrated to the United States four years ago during the COVID-19 pandemic. She is passionate about fostering collaboration, advancing women in STEM, and driving operational excellence to improve women’s health worldwide.

Lisa leads the Corporate Environmental, Social and Governance (ESG) strategy at Insulet, developing innovative new business models and ecosystems to sustain positive global impact. She has held Executive roles in Sustainability and CSR in Supply Chain Operations at Cisco, Dell Technologies, and EMC Corporation. Prior roles include IT portfolio management, internal consulting and leadership positions at Massachusetts General Hospital and Washington University School of Medicine, including consulting to the World Health Organization.

Gabriele Brambilla, MBA, is Alira Health’s Chief Executive Officer and Co-Founder. As CEO, Gabriele evangelizes Alira Heath’s mission—humanizing healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance.

 In 2018, he co-founded the MetroWest Life Sciences Network, a regional collaboration of healthcare and life science-based organizations, municipalities, and economic and business development organizations in Boston’s MetroWest, where Alira Health is headquartered. As the network’s current chairman, Gabriele fosters collaboration, innovation, and entrepreneurship in this critical life sciences ecosystem.

 He is also on the Board of Directors of MassMedic, EnlightenVue, WoundForce, Firefly Innovations, X-Cor Therapeutics, Computational Life, SMOC, and the co-founder of Inter Academy MetroWest Boston soccer program.

 Gabriele began his career in pharmaceuticals, working for an Italian firm based in Shanghai, and developed his deep industry expertise through roles with medical device and digital health technology practices.

 He holds a BA in Political Science from the University of Pavia, a master’s degree in International Affairs from the I.S.P.I., and an MBA from Post Graduate SDA Bocconi in Milan, Italy.

Lori Chmura is an accomplished healthcare executive with more than 30 years’ experience in the medical device industry. She currently leads Nyra Medical, an early stage cardiovascular company focused in the structural heart space, as its CEO. In addition, she serves as the Chairman of Bluewind Medical, a commercial stage women’s health company.

Previously she served as President and Chief Executive Officer at Soundbite Medical Solutions, a privately held medical device company in Montreal, Canada.  Lori provided strategic leadership to transform the business resulting in the receipt of FDA clearance of its revolutionary device for the treatment of calcific occlusive cardiovascular disease using shock wave, energy while securing non-dilutive capital for the company through the signing of an exclusive licensing partnership with a reputable Chines cross border fund.

Prior to Soundbite, Ms. Chmura led Dune Medical Devices as the Chief Executive Officer, and member of the Board of Directors exiting with a sale of the company’s business in April 2020. She has held escalating leadership roles within several leading medical device companies, including Medtronic, Covidien and Johnson and Johnson, with extensive experience in leading and growing medical device businesses in the United States and globally across cross functional areas such as commercialization strategies, research and development activities, regulatory affairs, and transfer to manufacturing, among others.

Recognized by the Southeast Medical Device Association as its “Woman of the Year” in 2017, Lori’s proven leadership, with a successful track record in leading, transforming, and growing global medical device businesses, has enhanced shareholder value among both large cap public companies as well as privately held, venture supported organizations.

Lori previously served on the Board of Directors, as a member of the audit committee, of OpSens Inc. (TSX:OPS), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology. As a member of the deal team, Lori worked on the sale to Haemonetics (HAE) in December of 2023 She also serves on the Executive Committee of the ADVAMED Women’s Executive Network Board (WEN) and is past

President-elect of the Board of the Atlanta Chapter of the Healthcare Businesswomen’s Association. Passionate about working with and developing young professionals, she also supports C-LEGS, a catholic leadership development program as a mentor to college students as they prepare for entry into their professional careers.

Lori received her MBA from Duke University and her BSN in Nursing from Southern Connecticut State University. As a lifelong learner, Lori has also participated in numerous advanced education programs from Harvard University, as well as other reputable institutions throughout the years. She has been married to her biggest supporter and lifelong partner for 34 years, sharing two beautiful grown children and one son in law.

Chris Coburn is Chief Innovation Officer of Mass General Brigham, an integrated health care system that includes Harvard University affiliates Brigham and Women’s Hospital, Massachusetts General Hospital, Massachusetts Eye and Ear, and McLean Hospital. Mass General Brigham is the nation’s largest academic research enterprise with over $16 billion in annual revenue, 1.5 million patient visits and more than $2.4 billion in research expenditures. It also has a managed care organization, out-patient facilities and community hospitals. 7,000 of its faculty are appointed at Harvard Medical School.

A member of the senior leadership team, Coburn is responsible for the commercial application of the unique capabilities of MGB’s 85,000 employees. His 140-person business development group’s activities include strategic industry collaborations, company creation, investing, translational development, commercial strategy setting, licensing, and innovation management. His group also manages a nearly $500 million venture fund.

Prior to joining Mass General Brigham, Mr. Coburn was founding director of Cleveland Clinic Innovations and served for 13 years as its executive leader. During his tenure, Cleveland Clinic spun off 57 companies that raised more than $700 million in equity financing. There were none before Coburn’s arrival. His team also managed an innovation alliance network in which Cleveland Clinic directly supported technology commercialization for healthcare systems throughout the United States. Previously he was Vice President at Battelle and served on the staff of Ohio Governor Richard Celeste.

Mr. Coburn serves on multiple boards. He and his wife Nancy have three grown children.

Antonio Sanchez-Cordero is a global healthcare private equity investor at Archimed, where he specializes in identifying and nurturing strategic investment opportunities in the medical devices and diagnostics sectors. With a robust background in corporate leadership, Antonio has held key roles at leading healthcare multinationals such as Thermo Fisher Scientific, Becton Dickinson and Werfen, focusing on business development, corporate strategy, and M&A.

Ed is a co-founder of Beta Bionics. Ever since his son developed type 1 diabetes at 11 months of age, Ed has been committed to building a bihormonal bionic pancreas. Ed has been a Professor of Biomedical Engineering at Boston University since 2004. He was an Assistant Professor of Mechanical Engineering at the University of Illinois prior to that. Ed received a Ph.D. in Applied Mechanics and a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, and an M.S. in Mechanical Engineering from Washington University in St. Louis.

Shuja Dawood is the Vice President of Business Development, Strategy and New Technologies at Boston Scientific, where he leads a team focused on mergers & acquisitions and venture capital activities for the company’s Cardiac Rhythm Management, Cardiac Diagnostics, and Electrophysiology businesses as well as strategy and integration of new technologies for the Electrophysiology business. Shuja’s team primarily focuses on identifying and driving growth opportunities that align with the business’s long-term objectives. He holds a Bachelor of Science degree in Bioengineering from the University of California, San Diego and a Master of Science degree in Biomedical Engineering from Johns Hopkins University.

Anthony is a Senior Vice President on ML Strategies’ federal advocacy team in Washington, DC. He works with clients to develop and implement effective messaging and legislative strategy. Anthony helps clients navigate the Congress and administration in pursuit of policy objectives and federal funding, as well as through congressional inquiries.

For well over a decade, Anthony has been working with Congress, the bureaucracy, and the media to advance client interests. He has represented major multi-national corporations, start-ups, non-profit organizations, industry coalitions, and labor unions from most major sectors of the economy. Anthony works extensively in health care, both reimbursement and regulation. He also represents clients in transportation, infrastructure, defense, technology, and manufacturing on issues including taxation, trade, and federal appropriations.

Prior to joining ML Strategies, Anthony served in government affairs and public relations roles at firms in Washington and Boston. He is active in Democratic politics, particularly in his home state of Massachusetts.

Michael is the Vice President of Healthcare Economics and Reimbursement for AtriCure, a surgical medical device company focused on treatment of atrial fibrillation.  Michael has responsibility for overall reimbursement, health economics, and market access strategy. Some of his groups work and collaboration with specialty societies has resulted in new CPT and MS-DRG payment codes.  Prior to his role at AtriCure he held leadership positions at Boston Scientific, Philips Healthcare, and Medtronic.

He earned his PhD at the University Florida in Applied Physiology.

Morgan Francis is a dynamic leader in the medical device industry, currently serving as the Director of Commercial Marketing for Arthroscopic Enabling Technologies at Smith + Nephew. With 13 years of experience in the medical device field, he has built a career marked by significant contributions across sales, global marketing, and commercialization. His expertise has been honed through a variety of roles, culminating in his current leadership of the downstream/launch strategy for all arthroscopic technologies within the United States. Morgan’s focus centers on both Ambulatory Surgical Centers (ASCs) and hospitals, where he spearheads the go-to-market execution for a comprehensive portfolio of products. These include cutting-edge visualization systems, precise resection tools, advanced fluid management solutions, and innovative patient positioning platforms, all essential components of modern arthroscopic procedures. His passion lies in bringing these critical technologies to market, ultimately improving patient care and advancing the field of arthroscopic surgery.

Founding Partner of Fraser Healthcare, a consulting firm dedicated to growth strategies for top-tier MedTech companies and private equity firms. With thirty years of experience in commercializing new healthcare technologies and services, Scott is expertly equipped to assist clients in crafting innovative healthcare delivery models and strategies for ambulatory surgery center and private equity backed MSO growth.

Before establishing Fraser Healthcare, Scott served as the President of Physicians Endoscopy, a Kelso private equity backed ASC management company that was sold to Optum/SCA. There, he spearheaded growth initiatives by developing a comprehensive business plan and executing strategic transactions that formed a new practice management MSO division within the company. Scott was also part of the founding executive team at EndoChoice Inc. (NYSE: GI) in 2007, where he held the position of Global Vice President of Commercialization. EndoChoice, a company focused on the ambulatory surgery center market, received accolades from Inc. Magazine as one of the fastest-growing companies in America for five consecutive years. The company, backed by Sequoia Capital, achieved a successful IPO (NYSE: GI) before being acquired by Boston Scientific Corporation in 2016. Prior to his time at EndoChoice, Scott was the Director of Marketing at Given Imaging (NASDAQ: GIVN), now part of Medtronic, where he played a crucial role in launching the groundbreaking PillCam Video Capsule.

Scott’s career in healthcare started at Boston Scientific, where he held various leadership positions in sales, marketing, and market development during a significant growth period for the company.

He earned a B.Sc. in management from Villanova University, where he was recognized as a NCAA Academic All-American scholarship athlete, and he also holds an MBA from Boston University.

Diana Gelston is the chief commercial officer of Best Buy Health for Best Buy Co. Inc. In her role, she is responsible for building and strengthening the company’s commercial relationships that aim to enable care at home for everyone.

Diana leads a large, diverse team in creating and executing high-impact, go-to-market strategies that support the company’s mission to enrich and save lives through technology and meaningful connections. At Best Buy Health, she is focused on developing integrated commercial strategies that support consumers wherever they are on their health journey and improve the care-at-home experience.

Previously, Diana has successfully launched and developed more than a dozen sales and marketing teams, with P&L’s of more than $2.1B, in tech, medical devices, digital health, and healthcare information systems at Amazon Business Healthcare, Fresenius Medical Care, Philips Healthcare, and other innovative start-ups.

Diana earned a bachelor’s degree from the University of Southern California and a certificate in Leadership Development and Business Administration from the University of Pennsylvania’s Wharton Business School.

Maureen Halligan is the Vice President of Advisory & Innovation Services at Cambridge Consultants, where she leads programs to define and delivery medical technology innovations. Maureen has over 10 years of experience in applying human-centered design approaches to identify unmet needs, translate these needs into product requirements, and implement solutions that meet requirements and promote an optimal user experience. She has worked on a myriad of medical technologies, with a focus in surgical innovations and digital health solutions. She holds a BS in Biomedical Engineering from the University of Virginia and an MS in Human Factors Engineering from Tufts University, where she previously taught Human Factors in Product Design. Maureen is a mother of two, and is passionate about creating mechanisms, communities, and innovations to better support women throughout and beyond the maternal care continuum.

Mary Anne Heino has served as a Director since August 2015, and became the Chairperson of our Board, the Chairperson of the Finance and Strategy Committee and a member of the Science and Technology Committee on March 1, 2024. She previously served as our Chief Executive Officer, a position she held from August 2015 until March 1, 2024, as our President and Chief Executive Officer, a position she held from August 2015 until March 2023, as our Chief Operating Officer, a position she held from March 2015 until August 2015, and as our Chief Commercial Officer, a position she held from April 2013 (when she joined the Company) until March 2015. Ms. Heino brings more than 30 years of diverse pharmaceutical industry experience to the Board. Prior to joining Lantheus, Ms. Heino held executive level roles at Angelini Labopharm LLC and Labopharm USA from February 2007 to March 2012. From May 2000 until February 2007, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson (“J&J”) company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and held increasing roles in Sales and Marketing through 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.

Caroline Irungu is a Global Commercial Strategist for medical devices and diagnostics at Dassault Systémes. Caroline joined Dassault Systémes from Stryker where she led efforts to drive change for more sustainability in healthcare including leading product launches for products specifically designed for sustainability. Prior to Stryker, Caroline was a Director of Product Management at Zimmer Biomet where she led the Extremities business. Earlier in her career, at Medtronic, Caroline had extensive experiences leading global product launches and driving adoption of new medical technologies. She began her career as an R&D engineer where she learned her love of the operating room and partnering with surgeons to make an impact on patients. This led her to a long career in sales where she provided support to surgeons across many cardiovascular therapies. Caroline earned her bachelor’s degree in Biomedical Engineering from Stevens Institute of Technology, and her Master of Public Policy degree from New York University.

Brian Johnson was named president of the Massachusetts Medical Device Industry Council (MassMEDIC) in July 2018. An accomplished author, media entrepreneur, Brian serves as the  association’s second chief executive officer in its history, managing its day-to-day operations and working with medical device industry executives in developing its policy agenda. Since its establishment in 1996, MassMEDIC has grown to 300 member companies – manufacturers and developers of medical products, suppliers, research institutions and academic health centers –  and has advanced the public policy interests of the New England medical device sector on Capitol Hill, Beacon Hill, and before various federal agencies. 

In 2007, Brian conceived and later launched MassDevice.com, where he been responsible for the strategic vision of the company, from inception through the summer of 2018, including leading the company through an acquisition in 2015 by WTWH Media.     

As publisher, Brian spearheaded the growth of MassDevice from 0 to 100,000+ readers each month and led the company to profitability in just 3 years and more than $2.8M in annual sales. In 2011, Brian conceived and launched DeviceTalks, a live-interview series featuring leaders in medicine. The event, which is held three times annually in Boston, Minnesota and Orange County, California, has attracted thousands of medical device executives to date and featured leaders from some of the world’s largest medical technology companies. Since 2015, Brian also founded and launched two additional magazines, Medical Design & Outsourcing and Drug Delivery Business News, bringing total readership under his supervision to over 1.5 million.  

Under Brian’s direction, MassDevice and its associated properties were widely recognized for its commitment to quality journalism. The editorial boards of the New York Times, NPR, Wall Street Journal, Washington Post have cited MassDevice’s coverage of issues pertaining to the medical device industry.  In 2012, MassDevice won a prestigious Communicator award in 2012 for excellence with its live web video series “Disruptors.”  

An experienced reporter and author, Brian has worked for The Associated Press, Boston Globe digital and The Eagle-Tribune newspaper, covering business and economics, local government and crime.  In 2017, his critically acclaimed first novel “MWD: Hell is Coming Home” was released by Candlewick Press. 

Brian resides in Brookline, Massachusetts with his wife and two young children.  

​

​

Ravi Kaushik is the VP, Global Head of Device and Digital Development and Product Strategy where he is responsible for driving innovation for Plasma Derived Therapies and leads a team of engineers, digital and product management organization. Ravi joined Takeda in 2021 as the VP, Global Program Leader, PDT Integrated Care Solutions where he has formed a Global Program team (GPT) to cross-functionally drive patient and donor centered integrated care solutions with devices/digital innovations to help drive better patient outcomes while growing the PDT business Earlier, Mr. Kaushik was the CEO for TransAsia Biomedical Ltd. (a large IVD company) where he led & drove the Strategy, Product Development & Launch Execution, Leadership Team Management, Business development & growth with P&L Responsibility (~ $120MM) and 1200 employees globally.

Earlier, Mr. Kaushik was with Medtronic as the Group Marketing Director, APAC & Country Director, India for the Diabetes business (insulin pump & CGM). He drove strategic growth for the ~$100 MM business and led innovative patient centric business models to improve solutions and services for Diabetes patients (value-based healthcare) across the APAC region.

Prior to that, Mr. Kaushik was at Baxter International (Baxalta-Shire) as Director for Strategy & Healthcare Innovation function for the Emerging Asia/India markets. He provided strategic leadership, identifying, and executing key market and patient centric innovation programs while aligning these initiatives with the global company strategic plan. He also led the commercial (P&L) of the $70MM Baxalta India with a 100+ member team when it was spun off from Baxter in 2015. Earlier, Mr. Kaushik was at GE Healthcare as the Director of Global Upstream Marketing (Maternal Infant Care), Emerging Markets leading multiple teams of product managers for disruptive medical device product innovation, driving market creation with organic growth across Asia & Africa. Prior to that Mr. Kaushik was with GE LED Lighting as a Global Product Marketing Manager, in Cleveland, USA leading several new product innovations in LED lighting for retail display.

Overall, Ravi has 25+ years of global leadership experience in P&L Management & strategic innovation in various roles/industries ranging from Healthcare (MedTech & Pharma), LED Lighting, & Industrial companies globally. Ravi has proven himself as a disruptive innovator, strategic thinker, inclusive and execution driven leader in business analytics, strategic planning, global marketing, new
product & business model innovation.

Over the past decade, Ravi has been recognized globally as India’s Top 20 Healthcare CEOs (Transasia) in 2020, Global transformative leader award (Medtronic) in 2018, Emerging Market Growth Leader award (Medtronic) in 2018, Healthcare Innovation speaker at World Federation of Hemophilia Congress (2016), Global CEO Award for “Imagining the possibilities” Business Model Innovation at Baxalta (Shire) (2015), CEO Award for Patient Centricity (GE Healthcare, India) in 2012 Mr. Kaushik holds an MBA from the prestigious Kellogg School of Management (Northwestern University) in Chicago. Mr. Kaushik also has graduate degrees of Master’s in mechanical engineering from the University of Wyoming and Bachelor’s in mechanical engineering from MS University, Baroda, India.

Justin Kelly currently serves as Noctrix Health’s Senior Vice President, Patient Access where he oversees market access strategy, government relations and reimbursement operations. Justin joined Noctrix Health in June 2023. Prior to joining Noctrix Health, Justin had extensive experience launching novel therapies and medical devices leading reimbursement and market access functions at Novocure, Sirtex Medical, Insulet Corporation and Genzyme Biosurgery. He holds a Master’s Degree in Global Business Administration from the Fletcher School at Tufts University as well as a Bachelor’s of Science in Nursing from the University of Massachusetts.

Paula LeClair is the Senior Vice President of HomeCare Service at Butterfly Network, Inc. Paula’s responsibilities encompass a broad spectrum of initiatives, from design and implementation of innovative service models to fostering collaborations with healthcare professionals, health plans and community stakeholders. Previously, Paula was US General Manager for Healthy.io, an Israel-based health tech startup, that is a leader in turning the smartphone camera into a medical grade device. As the first U.S. employee, Paula set the vision and business strategy for the U.S. team and successfully launched its at home Kidney Disease Test.

Paula is an innovative and versatile executive leader with a proven track record of driving growth and profitability across a range of corporate environments, including Fortune 500 companies, high-growth startups, and small entrepreneurial ventures within sectors such as digital health tech, medical devices, AI solutions, and high tech.  She has a deep understanding of the complexities of the US healthcare system, including reimbursement, delivery, and regulation across all areas of the healthcare continuum, from physicians and pharmacies to administrators, payers, and economic buyers.

Paula holds a Master of Healthcare Delivery Science from Dartmouth College, a Master of Business Administration from Bentley University, a Bachelor of Science in Mechanical Engineering from University of Notre Dame and a Bachelor of Arts from Saint Anselm College. She is a member of the American Diabetes Association Community Leadership Board of New England.

Mira Leiwant currently serves as VP of Regulatory Affairs, Quality and Clinical Affairs for Anika Therapeutics. Anika is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Her responsibilities include strategic regulatory compliance planning and assessment for all Anika’s products, developing quality systems to meet ever-changing global regulatory demands, and conducting clinical research to support regulatory and commercial demands. She has over 25 years’ experience in the medical device industry, with varying roles from R&D to Quality Assurance and Regulatory Affairs, for products in the therapeutic areas of cardiology, wound care, regenerative medicine, and oncology. She earned both Bachelor’s and Master’s degrees in Mechanical Engineering from Cornell University, and holds a Regulatory Affairs Certification (RAC).

Bryan Lord is the CEO of Pristine Surgical – a medical device company on a mission to simplify endoscopy. Prior to joining Pristine Surgical, Lord co-founded Orthopedic Venture Partners, an investment fund which invests in disruptive orthopedic technologies; New Venture Advisors, a corporate development and venture services firm; and the Innovation Alliance, a coalition of high-technology companies focused on strengthening intellectual property rights. He has served as an executive at Oak Ridge National Laboratory and AmberWave Systems Corp., an advanced semiconductor spin-out from MIT. Lord holds an MBA from The Wharton School at the University of Pennsylvania, a JD from Notre Dame Law School and a BA from Concordia College in Moorhead, Minn.

 Michael Minogue is the President and CEO of Minogue Consulting, LLC. and Heartwork Capital, with over 30 years of industry experience leading with his “Patients First” and “Dream Big, Execute Bigger” mindset. By training individuals how to adapt, execute, lead, and manage, Michael empowers and inspires people to achieve their best results with integrity, creativity, intellect, and grit. 

For nearly 19 years, Michael served as Chairman, President, and CEO of Abiomed, Inc. (NASDAQ: ABMD), which revolutionized the field of heart recovery through the development of Impella®, the world’s smallest heart pumps. He devoted himself and the company to recovering hearts and saving lives, leading in technology and innovation, growing shareholder value, and sustaining a winning culture. This culture and vision led Abiomed, Inc. to be one of the fastest growing, GAAP profitable MedTech companies, generating total shareholder return of 2,467% since April 2004 and 1,172% in the last 10 years. 

Under Michael’s leadership from 2004-2022, Abiomed, Inc. treated over 250,000 patients, received multiple exclusive FDA approvals, expanded their patent portfolio to over 2,000 patents and over 2,000 pending, increased revenue from $22M to $1.2B, and grew market capitalization from $170M to approximately $17B. His tenure culminated in negotiating with Johnson & Johnson, resulting in the largest all-cash acquisition in MedTech history (16.9x EV/Revenue | 64.4x EV/EBITDA) and the 7th largest MedTech deal of all time. 

Prior to Abiomed, Inc., Michael spent 11 years with General Electric Healthcare, leading in roles of sales, marketing, product development, engineering, software, and services. While there, Michael filed three patents. He also served as an Infantry officer in the U.S. Army, where he earned multiple distinctions including Airborne, Ranger, and Bronze Star as the lead navigator and Platoon Leader for the 24th Infantry division in Desert Storm. Michael received his B.S. in Engineering Management from the United States Military Academy at West Point and his M.B.A. from the University of Chicago. 

Michael currently serves on the boards of Insulet Corporation (NASDAQ: PODD), St. John’s Preparatory School, Crane Estate Advisory Board, and MedTechVets. In addition, Michael is a co-owner of BOOST Oxygen and serves as General Partner for Essex Woodlands. Previously, Michael served on the board of the medical device industry association, Advamed (2007-2023) and as Chairman (2021-23). He has also served on the boards of LifeCell, Bioventus, and Medical Device Innovation Consortium, (MDIC, Chair-2016-19). 

Michael is passionate about supporting education, military veterans and causes for children. In 2012, Michael co-founded MedTechVets, a 501(c)(3) nonprofit organization that helps military veterans discover career opportunities in MedTech. In 2015, he co-founded the Mike and Renee Minogue Foundation to support faith-based education and pediatric care through partnerships with the Catholic Schools Foundation, WonderFund, Boston Children’s Hospital, and multiple others. 

Michael is married with five children and enjoys reading, running, coaching, and skiing. 

Joe Mullings has been building companies and careers since 1989. He is the Founder, Chairman and CEO of The Mullings Group, including TMG Search and Dragonfly. The search firm, with over three decades in the industry, is responsible for more than 9,000 successful searches in medtech / healthtech / life sciences with clients ranging from multi-billion-dollar companies to emerging high-tech organizations worldwide. TMG’s international presence and work with over 900 companies allow them to provide solutions to the clients they partner with across the globe.

As the first search firm to integrate media and talent access, Dragonfly was launched as a media production company, complete with a state-of-the-art studio, for use by clients and partners for attention and awareness. Dragonfly is the media machine behind the 7-time Telly Award winning video docuseries, “TrueFuture,” of which Joe is the host. He is also the founder of TMGPulse, a MedTech news and opinion website.

Joe is an active member of the medtech and investor community. He sits on industry boards and serves as an adviser to many emerging tech startups and technology accelerators as well as being an angel investor. He holds an engineering degree from The University of Dayton, Ohio.

Jason is a seasoned medical device leader with 20 years of experience in product development. He drives disruptive innovation at Insulet, where he was the lead designer of the Omnipod® Insulin Management System and product lead for the Omnipod 5 Automated Insulin Delivery (AID) system, the only AID system indicated for type 1 and type 2 diabetes.

Marie retired in February 2021 after 27 years of service at Medtronic. She served as the Senior Director of Supplier Outreach for Medtronic, responsible for developing and executing long-term Medtronic supplier outreach programs, including efforts around Responsible Supply Management and Supplier Diversity. During the time Marie led the Supplier Diversity program, Medtronic has been recognized twice as a Top Corporation supporting Women Owned Businesses and she has served in leadership roles and numerous engagements supporting various Supplier Diversity and industry advocacy organizations.

Marie has progressed in her career at Medtronic through several positions with increasing responsibility in a number of functions including Finance, Sales & Contract Administration, Customer Service, Global Supply Chain, Supplier Quality, and Supply Management roles. Her passion and most rewarding roles have been in her capacity to champion, mentor, and advance members of her team.

Marie currently serves as the Chief Commercial Officer for PiSA USA representing Centerpiece and PiSA who offer world class contract manufacturing and EtO sterilization processing. Marie partners with her experienced and professional colleagues supporting Top tier OEMs along with startup companies for their development, manufacturing and sterilization needs.

Marie has an MBA from Bentley University and an undergraduate Finance degree from Binghamton University. Marie also earned an Executive MBA certification from Wharton University. She’s also a Certified Management Accountant (CMA) and CPIM (Certified in Production and Inventory Management).

Marie has served on the Board of Directors of MassMEDIC for over 12 years and served as Chair of the Board in 2019- 2021. Marie was recognized in the 2018 and 2019 top 100 list of women executive leaders in the medtech industry.

Bill Peine leads the Robotic Technology Development Center at Medtronic, where he brings together experts from around the globe to accelerate innovation and enterprise-wide robotic strategies. He also serves as the Vice President of Research and Technology for the Surgical Operating Unit, fusing cutting-edge robotic-assisted technology and AI with groundbreaking surgical devices. Both roles enable him to deliver on his passion – leading innovation across multi-disciplinary teams to develop breakthrough technologies and products that deliver better outcomes and improve people’s lives.

Since he joined Medtronic more than 10 years ago, Bill has driven the development of the Hugo^TM Robotic Assisted Surgery system for soft-tissue, to deliver the benefits of minimally invasive surgery – fewer complications, shorter hospital stays, and a faster return to everyday life.

Additionally, he has been inducted into the Bakken Society, the highest technical honor at Medtronic. The Society recognizes technical employees for their contributions to the company and to the healthcare technology industry.

Peine’s first foray into robotics was at Harvard University where he earned his Doctorate in Engineering Sciences. After completing his PhD, he worked at several start-up medical device companies, some fueled by his own doctoral research and one that was purchased by Medtronic. He was a tenure track professor of Mechanical Engineering at Purdue University – where he had also completed his BS in Electrical Engineering several years prior. While teaching at Purdue, he focused on researching novel surgical robotic technology and algorithms for image-guided surgery.

Throughout his career, he has authored of over 100 patents and peer reviewed publications.

Dr. Brian Quist is a Senior Director of Research and Development at Smith+Nephew in Sports Medicine. Within the Arthroscopic Enabling Technology group, he leads the Advanced Technology Development, Systems Engineering and Systems Verification groups. In this role, he is helping advance the purpose of Smith+Nephew – “Life Unlimited” – by using technology to take the limits off living for patients and helping medical professionals do the same.

Brian began his career in 2012 as a consultant at the Boston Consulting Group in the Chicago office. In 2015, he became a Project Leader. While at BCG, he focused on healthcare and had experiences in strategy, R&D portfolio optimization, M&A diligence and large-scale operating model transformations.

In 2017, Brian joined Smith+Nephew as the Director of Digital Health supporting the President of R&D. He transitioned into Sports Medicine to start the Systems Engineering and Systems Verification groups in 2019. In 2020, he added management of the Advanced Technology Development group.

Brian has a PhD in Biomedical Engineering from Northwestern University. He was awarded a National Science Foundation Graduate Research Fellowship and a Ruth L. Kirschstein National Research Service Award for Individual Predoctoral Fellows during his doctoral work at Northwestern. He holds a Bachelors degree in mechanical engineering with a minor in bioengineering from the University of Illinois Urbana-Champaign (UIUC). He also holds a certificate for Management for Scientists and Engineers from the Kellogg School of Management at Northwestern University.

Juliane Ray is the General Manager of Clarivate’s Medtech business unit.  Clarivate Medtech connects data, technical and market expertise and workflow tools to bring commercially successful medical devices and technology to patients faster.  We partner with the Medtech industry to boost portfolio value and growth, accelerate their path to market and maximize commercial success.

Juliane has held several global leadership roles in the medical device and technology industries.  She began her career in consulting at Deloitte and ZS Associates, where she collaborated with life sciences executives on commercial strategy.  She spent more than 10 years leading marketing, strategy and operations teams at Cardiovascular Systems Inc (Abbott), American Medical Systems (Boson Scientific) and Landauer (Danaher) before joining Veeva as Vice President of Medtech Commercial Strategy in 2021 and Clarivate in 2024.

Juliane holds an MBA from the University of Virginia (Darden School of Business) and a BA in economics and international studies from Macalester College.  She also serves on the Board of Directors at the Jungle, a nonprofit theater in her home city of Minneapolis, Minnesota.

Colleen Riley is a healthcare executive and innovative leader with over 25 years of experience. Dr. Riley’s medical device expertise sits at the intersection of clinical and technical product development and Fortune 500 corporate leadership. Most recently as Senior Vice President and Chief Technology Officer at embecta (NASDAQ: EMBC), the team successfully spun-off the Diabetes Care business from Becton Dickinson, establishing a stand-alone company that continues to provide life-saving insulin injection devices to over 30 million people worldwide. 

Previously, Dr. Riley was the Senior Vice President of Innovation and Development for Terumo Blood and Cell Technologies. Under her leadership she advanced both existing and new product platforms beyond traditional scope of medical devices and therapy manufacturing to include services, software, and data management.  Her career includes pivotal leadership roles at Stryker Orthopaedics, Novartis AG and Johnson & Johnson where she drove innovation, advanced product portfolios including robotics and 3D printing and led digital transformations. 

Colleen earned a Bachelor of Arts in Chemistry, a Master of Science in Physiological Optics and an OD, Doctor of Optometry, degree from Indiana University.

A high-energy, connection-driven, non-profit executive, with a background in life sciences, technology and robotics engineering, Rachel joined MassMEDIC as Vice President in February 2020. During her tenure, the organization has tripled its headcount and increased its operating budget by more than 40%. Rachel joined the organization just weeks before the COVID-19 pandemic shut down all in-person events, and pivoted its in-person events strategy, launching a virtual events campaign to serve members and keep the medtech community connected.   

Promoted to Chief Operating Officer of MassMEDIC in 2021, Rachel is responsible for executing the organization’s strategy, including cultivating community partnerships and employee development.  She guides the direction and execution of the organizations programming and community collaborations, including Think Tanks on patient engagement, Working Groups around digital health, and she leads the MassMEDIC’s IGNITE Accelerator Program.    

As President of MassMEDIC IGNITE, one of medtech’s most successful accelerators, it has been her honor to help women- and minority-led ventures, raise more than $100M in the past two years. Their goal, and hers, is to drastically improve how medicine is practiced and challenge the standard of care.  

Rachel has spent the last 15 years in life sciences, primarily focusing on promotion of this important industry through business development and marketing. Through roles at Delve, Acorn Product Development and MPR, her skills have been centered on developing new strategic relationships, growing teams, and initiating thought leadership initiatives to drive awareness.  

​

​

Kate Rumrill is a seasoned executive, with 35 years of experience in the Medical Device and Pharmaceutical Industry. She began her career as a Toxicologist with companies such as Sterling Winthrop and Eli Lilly & Company. She later transitioned to focus on clinical research, holding various roles over the years, from CRA to Vice President of Medical Affairs. Most recently, Kate was the President and CEO of Ablative Solutions, Inc., a clinical stage startup company, developing a novel renal denervation technology for the treatment of hypertension. She has extensive experience in preclinical and clinical programs, product development and new product launches. Kate holds a BS degree in both Biology and Psychology from the State University of New York and post graduate coursework through Harvard Business School.

Todd Saunders serves as the Vice President of Marketing at Osteal Therapeutics, a clinical-stage biopharmaceutical company specializing in novel musculoskeletal therapeutics for orthopedic infections. He joined the company in June 2022, bringing over 20 years of experience in the medical device market.

Prior to his role at Osteal Therapeutics, Todd was the Director of Strategic Marketing at Providence Medical Technology, a medical device company focused on innovative solutions for high-risk patients with cervical spine pathology. Prior to this, Todd co-founded Medvest, a venture capital firm that invests in technology companies with potential to improve patient outcomes while decreasing healthcare costs. Early in his career, Todd worked for GE Healthcare’s surgical navigation group before co-founding Neuraxis Medical (now Hypoflo).

Mr. Saunders received a Bachelor of Engineering and Master of Engineering Management (MEM) from the Thayer School of Engineering at Dartmouth College.

Holly is a Senior Partner at The Mullings Group, and has been a part of the firm for 25+ years. She believes the most productive and fulfilling organizations are built on the complementary forces that make up a team. Her bidirectional approach to each search allows her to put the best interest of both the individual and the company at the center of her team’s work. She is passionate about the medical device industry, which works to elevate health and healthcare, the individual careers we help build, and the team at TMG. These individuals keep Holly committed to being better every day.

Continuously giving back to the industry, Holly is a member, guest speaker, and advocate for MassMEDIC’s Women in Medtech organization. She also hosts two podcasts, The Power Curve, and Tech Talks with Holly Scott.

Holly is a graduate of the University of Florida with a psychology major and a business minor. She has also been awarded Certified Senior Account Manager (CSAM) by MRINetwork, an international network of recruiting firms.

Paul Seltman joined Smith+Nephew in 2010 and currently serves as Senior Vice President, Global Public Policy & Government Affairs. Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue.

Seltman has over three decades of experience in Washington. Prior to joining Smith+Nephew, he was Director, Public Policy and Government Relations, at Becton, Dickinson and Company in Washington, D.C. His private sector experience also includes serving as Counsel with the law firm of Drinker Biddle & Reath and Associate Vice President for Payment and Policy with the Advanced Medical Technology Association (AdvaMed).

From 1993-2001, Seltman held a range of positions with Democratic lawmakers on Capitol Hill and in the Clinton Administration.  He served as a Special Assistant in the Office of the Assistant Secretary for Legislation at the Department of Health and Human Services, Counsel for both the Senate and House Budget Committees, and Deputy Chief of Staff to former Congressman Major Owens (D-NY).

In between his stints in the public and private sectors, Seltman accepted a fellowship with the Robert Bosch Foundation in Germany, where he spent a year working with government and industry leaders on health care policy matters.  During that year, he achieved fluency in German.  Seltman received his undergraduate degree from the University of Michigan and law degree from American University.

Amy Siegel is CEO & co-founder of S2N Health, a company providing AI-powered software and strategy services to medical technology companies. Since its founding in 2011, S2N Health has worked with more than 180 companies, bringing valuable insights to drive business growth. Amy’s 25+ years of experience in the healthcare industry includes VP of Marketing roles at Aspect Medical (Covidien) and Seventh Sense Biosystems, and 10 years of strategy consulting with Health Advances and Monitor Company (Deloitte). Prior to her healthcare career, Amy was a policy analyst with the U.S. Export-Import Bank. Amy earned a B.A. from Tufts University and an MA from the Fletcher School of Law and Diplomacy following a Fulbright year (Germany). Amy is involved in several organizations as a mentor, advisor, and guest lecturer, including Harvard iLabs, UCLA, Columbia, BU, Tufts, U. Mass, Advamed, MassMEDIC, MedTech Innovator and German Accelerator.

Mike Sroczynski is MHA’s Executive Vice President and General Counsel. He is responsible for the strategic direction and management of MHA’s lobbying, legal and regulatory affairs, and policy development. On behalf of the organization, he is an active participant in numerous business, healthcare, and advocacy coalitions.

Mike has been a leading advocate for the hospital community both in Massachusetts and nationally for more than two decades. Prior to joining MHA, he served as legislative counsel in the Massachusetts State Senate.

He serves on the board of directors for the Professional Liability Foundation, the Vision Coalition Massachusetts, and the Massachusetts Chapter of the Arthritis Foundation. He also serves on the advisory committee of the Massachusetts Health Council and is a past president of the organization.

He is a graduate of the Syracuse University College of Law and the Whitman School of Management at Syracuse University.

Dr. Raj Stewart is a seasoned expert in the life sciences industry, currently leading market access engagements for IQVIA MedTech. He provides strategic expertise in optimizing coverage, coding, and reimbursement for medical devices, diagnostics, and innovative cell and gene therapies across over 30 APAC, EU, North American, and South American markets.

With over a decade of experience, Dr. Stewart has consulted for MedTech manufacturers, investors, and clinical professional societies. He has been a key contributor to favorable national and regional Medicare policies in six therapeutic areas and has secured premium access and payment for multiple distribution channels. His areas of expertise include market sizing, reimbursement strategy, evidence generation, and competitive intelligence.

He holds a PhD in Neuroscience from Brandeis University and a BS/BA in Biochemistry & Molecular Biology and Philosophy from the University of Maryland, Baltimore County.

Howard Tang serves as the Global Strategic Marketing Senior Manager at Johnson & Johnson MedTech, where he spearheads the identification of emerging trends and the development of global product portfolio strategies for orthopedic soft tissue repair devices and implants. With over 15 years of experience at J&J, Howard has been instrumental in bringing to market dozens of innovative products in the shoulder and knee arthroscopy sectors, including the world’s first self-tensioning suture.

Prior to joining J&J, Howard was a management consultant at PRTM (now PwC Consulting) and served as a technology portfolio manager at The Boeing Company. In these roles, he gained deep insights into market dynamics and product strategy, equipping him to drive impactful innovations in the med tech field.

Howard holds an MBA from the Massachusetts Institute of Technology’s Sloan School of Management and earned both his Bachelor’s and Master’s degrees in Engineering from the University of Michigan.

Shalene provides thought leadership, drives R&D and service offerings for Battelle’s growing PFAS and other potential emerging contaminants program. She has more than 25 years of experience in environmental consulting that includes 16 years of providing PFAS strategic management services to government and commercial clients across four continents that includes training 1,000 professionals.

Mr. Usen has extensive commercial and operational experience with a proven track record of leading large, complex global businesses across several highly regarded medical device companies.

He is currently the President & CEO of Adagio Medical (Nasdaq: ADGM), a leading innovator with proprietary catheter ablation technologies for treatment of cardiac arrhythmias, focusing on ventricular tachycardia.

Prior to Adagio, Todd was the President & CEO of Minerva Surgical, a women’s health organization. He led a complete restructuring of the organization, including raising $45 million of PE equity to take the company from public to private, while growing top line growth.  Prior, he spent four years as the Chief Executive Officer of Activ Surgical, a digital surgery company focused on advanced surgical imaging and AI, where he oversaw the FDA/CE clearance of its ActivSight technology, as well as leading four fundraising rounds totaling over $92 million. From 2015 to 2019, Mr. Usen was President, Medical Systems Group, for Olympus Corporation of the Americas, where he took charge of a complex $2B+ business and restructured the company for leaner growth and investment, drove successful mergers and acquisitions activity, led the expansion from 6 medical divisions to 11 in 3.5 years. Prior to that, Mr. Usen served in executive positions including President, United States Orthopedics, Senior Vice President & General Manager, Joint Reconstruction, and Senior Vice President Sports Medicine at Smith and Nephew, and Vice President Sales and Director of Sales at Boston Scientific Corporation.

Todd is currently the Executive Chairman of Rob Surgical, the Chairman of NeoPredics, an independent board director at Alesi Surgical, The Executive Chairman at MassMEDIC, the largest regional MedTech association in the United States. He serves as an advisor for The Cleveland Clinic Innovations and Ventures team, as well Avertto Medical.

Mr. Usen holds a BS in Marketing from the Isenberg School at the University of Massachusetts and did his MBA work at Pepperdine University.

Todd is married to Melissa, and they have three children, Morgan, Rachel and Tyler.

Peter brings more than 20 years of experience in the medical device and biopharmaceutical industry.

Prior to VCI, Peter served as the U.S. commercial vice president at Cordis. In addition, Peter has held senior sales roles at St. Jude Medical Corporation, AGA Medical Corporation and Covidien Healthcare (formerly Tyco Healthcare), among other leading health care companies.

Peter has proven experience driving commercial growth; building and leading diverse organizations of over 300 individuals, managing revenues exceeding $500 M and representing product offerings with C-level administrators. Peter received a Bachelor of Arts in Economics from the University of Massachusetts and completed the Columbia University Executive Management Program.

Jeff Valk is co-founder and CEO of Admetsys. Prior to taking the helm of Admetsys, he was the company’s Chief Technologist, responsible for development of its automated glucose control and continuous diagnostics system for hospital care and the state-of-the-art informatics and network monitoring technologies that support it. Jeff is a hardware and software engineer by background, specializing in the design of adaptive systems and has technical expertise in areas including machine intelligence, robotics, distributed systems, and human-computer interaction.

Mr. White was named President of the ZOLL Acute Care Technology division in April 2024, after serving as President of ZOLL Resuscitation for more than five years. He joined ZOLL as Vice President of Marketing in 2012 with responsibilities for the global marketing and strategy of the company’s resuscitation portfolio. Prior to ZOLL, Mr. White led North American marketing efforts at Haemonetics. Earlier, he held general management and marketing leadership positions at Orthofix and Medtronic cardiology. Mr. White has also served as a submarine officer in the U.S. Navy and holds an MBA and a B.A. from Harvard University.